Comparison of Pulsed and Thermal Radiofrequency for Trigeminal Neuralgia
Launched by ZAGAZIG UNIVERSITY · Nov 10, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two types of treatments for trigeminal neuralgia, a condition that causes severe facial pain. The researchers want to find out whether Pulsed Radiofrequency (PRF) alone or a combination of Pulsed and Thermal Radiofrequency (PRF + TRF) is more effective in relieving pain for patients. They will also look at how safe these treatments are and if either option leads to fewer complications. Participants will receive one of the treatments targeting the trigeminal nerve and will be followed for three months to assess their pain relief and overall well-being.
To be eligible for this trial, participants must be adults aged 18 to 60 who have been diagnosed with trigeminal neuralgia and have experienced significant facial pain for at least six months. They should be able to provide consent and commit to attending follow-up visits. However, individuals with certain conditions, such as those caused by tumors or previous surgeries for trigeminal neuralgia, or those who are pregnant or have allergies to the treatment materials, cannot participate. This trial is currently recruiting participants, and it aims to help improve treatment options for those suffering from this painful condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-60 years.
- • Diagnosis of classical trigeminal neuralgia, as per the International Classification of Headache Disorders criteria
- • Patients experiencing unilateral, episodic facial pain for at least six months with a Numeric Rating Scale (NRS) score greater than 6, despite medical treatment.
- • Able to provide informed consent.
- • Agree to follow the study procedures and attend follow-up visits.
- Exclusion Criteria:
- • Patients with secondary trigeminal neuralgia (e.g., due to tumors, multiple sclerosis).
- • Previous surgery or radiofrequency treatment for trigeminal neuralgia.
- • Pregnant or breastfeeding women.
- • Known allergies to anesthetics or other agents used in the procedure.
- • Significant psychiatric disorders that may interfere with pain assessment or study participation.
- • Coagulopathy or use of anticoagulants that contraindicate the procedure.
About Zagazig University
Zagazig University, a prominent educational and research institution located in Egypt, plays a pivotal role in advancing medical knowledge and promoting health innovations through its clinical trials. With a commitment to excellence in research, the university leverages its diverse expertise and state-of-the-art facilities to conduct rigorous clinical studies that aim to improve patient care and outcomes. By fostering collaboration among multidisciplinary teams, Zagazig University contributes significantly to the global medical community, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zagazig, Sharkia, Egypt
Zagazig, El Sharkia, Egypt
Patients applied
Trial Officials
Ahmed A Bessar, MD, PhD
Principal Investigator
Assistant Professor of Diagnostic and Interventional Radiology, Zagazig Uni.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported